Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

被引：0
|
作者：
Garcia, M. [1 ]
Schmid, S. [1 ]
Hueniken, K. [1 ]
Zhan, L. [1 ]
Balaratnam, K. [1 ]
Khan, K. [1 ]
Fares, A. [2 ]
Chan, S. [1 ]
Smith, E. [1 ]
Aggarwal, R. [1 ]
Brown, M. C. [1 ]
Patel, D. [1 ]
Sacher, A. [1 ]
Bradbury, P. [1 ]
Shepherd, F. A. [1 ]
Leighl, N. [1 ]
Liu, G. [1 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Famerp, Ctr Oncol Hosp Base, Sao Jose Do Rio Preto, SP, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
NSCLC; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.05
引用
收藏
页码：S1107 / S1108
页数：2
相关论文
共 50 条
  • [21] Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
    Yu, H. A.
    Baik, C.
    Kim, D. -W.
    Johnson, M. L.
    Hayashi, H.
    Nishio, M.
    Yang, J. C. -H.
    Su, W. -C.
    Gold, K. A.
    Koczywas, M.
    Smit, E. F.
    Steuer, C. E.
    Felip, E.
    Murakami, H.
    Kim, S. -W.
    Su, X.
    Sato, S.
    Fan, P. -D.
    Fujimura, M.
    Tanaka, Y.
    Patel, P.
    Sternberg, D. W.
    Sellami, D.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 437 - 447
  • [22] Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
    De Ruysscher, Dirk
    Wanders, Rinus
    Hendriks, Lizza E.
    van Baardwijk, Angela
    Reymen, Bart
    Houben, Ruud
    Bootsma, Gerben
    Pitz, Cordula
    van Eijsden, Linda
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1958 - 1961
  • [23] Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
    Shoko Sonobe Shimamura
    Takehito Shukuya
    Tetsuhiko Asao
    Daisuke Hayakawa
    Kana Kurokawa
    Shiting Xu
    Keita Miura
    Yoichiro Mitsuishi
    Ken Tajima
    Rina Shibayama
    Naoko Shimada
    Fumiyuki Takahashi
    Kazuhisa Takahashi
    BMC Cancer, 22
  • [24] L858R epidermal growth factor receptor (EGFR) mutations as a favorable prognostic factor of relapse-free survival in resected non-small cell lung cancer (NSCLC)
    Lee, Young Joo
    Cho, Young Chul
    Jeong, Jae Heon
    Kim, Se Hyun
    Kim, Hyun Ki
    Choi, Hye An
    Shin, Sang Joon
    Sohn, Joo Hyuk
    Kim, Joo Hang
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3541S - 3541S
  • [25] Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma
    Szentkereszty, Marton
    Ladanyi, Andrea
    Galffy, Gabriella
    Tovari, Jozsef
    Losonczy, Gyorgy
    LUNG CANCER, 2024, 192
  • [26] Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma
    Yang, Yu-Xian
    Zheng, Yu-Zhen
    Gao, Tian-Tian
    Liu, Shi-Liang
    Xi, Mian
    Liu, Meng-Zhong
    Wang, Jun-Ye
    Qi, Shu-Nan
    Yang, Yong
    Zhao, Lei
    CANCER MEDICINE, 2022, 11 (20): : 3751 - 3760
  • [27] Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
    Shimamura, Shoko Sonobe
    Shukuya, Takehito
    Asao, Tetsuhiko
    Hayakawa, Daisuke
    Kurokawa, Kana
    Xu, Shiting
    Miura, Keita
    Mitsuishi, Yoichiro
    Tajima, Ken
    Shibayama, Rina
    Shimada, Naoko
    Takahashi, Fumiyuki
    Takahashi, Kazuhisa
    BMC CANCER, 2022, 22 (01)
  • [28] An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome
    Han, B.
    Yan, B.
    Chu, T.
    Zhong, H.
    Zhang, W.
    Shi, C.
    Wang, H.
    Zhang, X.
    Gu, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1647 - S1647
  • [29] Factors associated with improving of 5-years overall survival in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
    Bondarenko, S. N.
    Rasumova, S.
    Stancheva, N.
    Slesarchuk, O.
    Vavilov, V.
    Gindina, T.
    Babenko, E.
    Alyanskiy, A.
    Barkhatov, I.
    Fedukova, Y.
    Smirnov, B.
    Zubarovskaya, L.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S479 - S480
  • [30] Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
    Christopher M. Gallagher
    Kenneth More
    Tripthi Kamath
    Anthony Masaquel
    Annie Guerin
    Raluca Ionescu-Ittu
    Marjolaine Gauthier-Loiselle
    Roy Nitulescu
    Nicholas Sicignano
    Elizabeth Butts
    Eric Q. Wu
    Brian Barnett
    Breast Cancer Research and Treatment, 2016, 157 : 145 - 156
12345